DexCom, Inc. $DXCM Stake Lessened by Groupe la Francaise

Key Points

• Groupe la Francaise cut its DexCom stake by 98.8% in the second quarter, selling 5,998,400 shares and retaining 75,630 shares worth approximately $5.1 million. Institutional investors collectively own 97.75% of DexCom.
• Wall Street remains broadly positive on DexCom, with a consensus “Moderate Buy” rating and an average price target of $88.71; recent targets range from $90 to $96 among bullish analysts.
• DexCom reported stronger-than-expected quarterly results, posting $0.70 in adjusted EPS versus $0.61 expected and $1.31 billion in revenue, up 13.1% year over year.

Groupe la Francaise lessened its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 98.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 75,630 shares of the medical device company's stock after selling 5,998,400 shares during the quarter. Groupe la Francaise's holdings in DexCom were worth $5,098,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Reflection Asset Management acquired a new position in shares of DexCom during the 4th quarter valued at $25,000. Ascentis Independent Advisors acquired a new stake in shares of DexCom in the first quarter valued at $25,000. MCF Advisors LLC acquired a new stake in shares of DexCom in the fourth quarter valued at $32,000. Wellington Grp LLC boosted its stake in DexCom by 778.7% during the first quarter. Wellington Grp LLC now owns 536 shares of the medical device company's stock valued at $34,000 after buying an additional 475 shares in the last quarter. Finally, DV Equities LLC bought a new position in DexCom during the fourth quarter valued at about $36,000. Institutional investors own 97.75% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on DXCM shares. UBS Group set a $96.00 target price on DexCom and gave the stock a "buy" rating in a report on Tuesday, July 28th. Barclays reaffirmed an "underweight" rating and issued a $64.00 price objective (down from $67.00) on shares of DexCom in a research note on Monday, May 18th. Truist Financial set a $93.00 target price on shares of DexCom and gave the stock a "buy" rating in a report on Friday, July 31st. Piper Sandler restated an "overweight" rating and set a $95.00 target price (up from $88.00) on shares of DexCom in a report on Friday, July 31st. Finally, BTIG Research restated a "buy" rating and set a $90.00 target price (up from $80.00) on shares of DexCom in a report on Friday, July 31st. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, DexCom presently has a consensus rating of "Moderate Buy" and a consensus price target of $88.71.

DexCom Price Performance

DexCom stock opened at $87.90 on Tuesday. The firm has a market cap of $33.17 billion, a PE ratio of 34.74, a P/E/G ratio of 1.47 and a beta of 1.42. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.43 and a current ratio of 1.73. The firm's 50 day moving average price is $81.60 and its two-hundred day moving average price is $72.49. DexCom, Inc. has a twelve month low of $54.11 and a twelve month high of $92.59.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.61 by $0.09. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The company had revenue of $1.31 billion during the quarter, compared to analyst estimates of $1.29 billion. During the same quarter last year, the business posted $0.48 EPS. The company's revenue for the quarter was up 13.1% on a year-over-year basis. On average, research analysts predict that DexCom, Inc. will post 2.64 EPS for the current fiscal year.

Insider Transactions at DexCom

In related news, Director Mark Foletta sold 2,000 shares of DexCom stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $85.32, for a total transaction of $170,640.00. Following the completion of the sale, the director owned 48,852 shares of the company's stock, valued at approximately $4,168,052.64. This trade represents a 3.93% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Brown sold 1,700 shares of the business's stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $75.55, for a total value of $128,435.00. Following the completion of the transaction, the executive vice president owned 106,353 shares in the company, valued at $8,034,969.15. This trade represents a 1.57% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 65,777 shares of company stock valued at $4,950,714 in the last three months. 0.28% of the stock is currently owned by insiders.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company's offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.